Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Inspire Medical Systems Inc / Equity Bottom-Up

<ul><li>Inspire Medical Systems reported second quarter 2026 results that were largely impacted by ongoing coding and reimbursement challenges, although some operational areas showed improvement.</li><li>The company’s revenue declined 7.6% year-over-year to $200.6 million, a downturn driven primarily by disruptions in prior authorization processes and uncertainties in billing codes.</li><li>Despite the revenue decline, Inspire managed to deliver adjusted operating income and positive cash flow ahead of expectations through disciplined cost management and a favorable product mix shift toward Inspire V systems.</li></ul>

Inspire Medical Systems reported second quarter 2026 results that were largely impacted by ongoing coding and reimbursement challenges, although some operational areas showed improvement.The company’s revenue declined 7.6% year-over-year to $200.6 million, a downturn driven primarily by disruptions in prior authorization processes and uncertainties in billing codes.Despite the revenue decline, Inspire managed to deliver adjusted operating income and positive cash flow ahead of expectations through disciplined cost management and a favorable product mix shift toward Inspire V systems.

Inspire Medical Launches Project Horizon — $30 Million In Capacity Gets Redeployed!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Inspire Medical Systems is a first-mover and market leader in hypoglossal nerve stimulation (HNS) for Obstructive Sleep Apnea (OSA), a large and undertreated market.</li>
  <li>The company has demonstrated a strong historical growth trajectory, recently achieving profitability and positive operating cash flow. However, it faces significant near-term headwinds from reimbursement and coding challenges related to its newer Inspire V system, which has led to a guidance reduction for 2026.</li>
  <li>While competition is emerging from other HNS device makers and potentially new therapies, Inspire's established market position, extensive clinical data, and growing physician and patient awareness provide a solid foundation for long-term growth, contingent on resolving current reimbursement uncertainties.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Inspire Medical Systems is a first-mover and market leader in hypoglossal nerve stimulation (HNS) for Obstructive Sleep Apnea (OSA), a large and undertreated market.
  The company has demonstrated a strong historical growth trajectory, recently achieving profitability and positive operating cash flow. However, it faces significant near-term headwinds from reimbursement and coding challenges related to its newer Inspire V system, which has led to a guidance reduction for 2026.
  While competition is emerging from other HNS device makers and potentially new therapies, Inspire's established market position, extensive clinical data, and growing physician and patient awareness provide a solid foundation for long-term growth, contingent on resolving current reimbursement uncertainties.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Inspire Medical Systems Inc (INSP US) - Aug 2026

<ul><li>Inspire Medical Systems reported first quarter fiscal 2026 results characterized by modest revenue growth alongside ongoing challenges related to coding, reimbursement, and a government-mandated prior authorization program (WISeR).</li><li>Revenue increased 1.6% year-over-year to $204.6 million, driven primarily by increased market penetration, although this growth was partially offset by estimated adverse impacts totaling approximately $20 million in the quarter due to coding uncertainties and WISeR-related delays.</li><li>The company highlighted its efforts to manage these external headwinds through disciplined cost control, prioritizing revenue-generating activities, and investments aimed at long-term growth, including enhancements to patient care pathways, marketing, digital product experience, and research and development.</li></ul>

Inspire Medical Systems reported first quarter fiscal 2026 results characterized by modest revenue growth alongside ongoing challenges related to coding, reimbursement, and a government-mandated prior authorization program (WISeR).Revenue increased 1.6% year-over-year to $204.6 million, driven primarily by increased market penetration, although this growth was partially offset by estimated adverse impacts totaling approximately $20 million in the quarter due to coding uncertainties and WISeR-related delays.The company highlighted its efforts to manage these external headwinds through disciplined cost control, prioritizing revenue-generating activities, and investments aimed at long-term growth, including enhancements to patient care pathways, marketing, digital product experience, and research and development.

Inspire Medical Systems’ $150 Million Reimbursement Hit: Can Inspire V Still Deliver?

<ul><li>Inspire Medical Systems, a company focused on innovating treatments for Obstructive Sleep Apnea (OSA), showcased mixed results and future projections in their recent quarter.</li><li>The financial and operational highlights for the third quarter of 2025 shed light on the company's current standing and future direction.</li><li>Inspire demonstrated a solid revenue performance for the third quarter, achieving $224.5 million, which marks a 10% increase from the same period last year.</li></ul>

Inspire Medical Systems, a company focused on innovating treatments for Obstructive Sleep Apnea (OSA), showcased mixed results and future projections in their recent quarter.The financial and operational highlights for the third quarter of 2025 shed light on the company's current standing and future direction.Inspire demonstrated a solid revenue performance for the third quarter, achieving $224.5 million, which marks a 10% increase from the same period last year.

Inspire Medical Systems: What The New Center Opening Strategy Reveals About The Next Growth Phase!

High Quality Stock Setups, Weekly Stock Bull Finder

Weekly Stock Bull Finder

High Quality Stock Setups

Finding high potential stock setups on quality companies

Thematic (Sector/Industry)

<ul><li>One of the lasting legacies of the COVID-19 pandemic was the acceleration of secular trends which were already in place prior to the start pandemic such as e-commerce, flexible working arrangements, streaming/entertainment at home, digital transformation, MRNA biotechnology, among others.</li><li>Many of these trends in place prior to the pandemic were turbocharged by a quick pivot and responses to adjust to the “new normal” disruption of the dealing with COVID-19 waves, lockdowns, and companies muddling through how to adapt their business model.</li><li>The aftermath of the combination of a bazooka fiscal and monetary stimulus has resulted in the Federal Reserve embarking on the most aggressive interest rate hiking campaign in decades in attempts to arrest and reverse inflation.</li></ul>

One of the lasting legacies of the COVID-19 pandemic was the acceleration of secular trends which were already in place prior to the start pandemic such as e-commerce, flexible working arrangements, streaming/entertainment at home, digital transformation, MRNA biotechnology, among others.Many of these trends in place prior to the pandemic were turbocharged by a quick pivot and responses to adjust to the “new normal” disruption of the dealing with COVID-19 waves, lockdowns, and companies muddling through how to adapt their business model.The aftermath of the combination of a bazooka fiscal and monetary stimulus has resulted in the Federal Reserve embarking on the most aggressive interest rate hiking campaign in decades in attempts to arrest and reverse inflation.

United States

Inspire Medical Systems, Inc. operates as a medical technology company. The Company develops implantable neurostimulation systems to treat obstructive sleep apnea. Inspire Medical Systems operates in the the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Inspire Medical Systems Inc (INSP US)

Inspire Medical Launches Project Horizon — $30 Million In Capacity Gets Redeployed!

Inspire Medical Systems reported second quarter 2026 results that were largely impacted by ongoing coding and reimbursement challenges, although...

Baptista Research

Primer: Inspire Medical Systems Inc (INSP US) - Aug 2026

Inspire Medical Systems is a first-mover and market leader in hypoglossal nerve stimulation (HNS) for Obstructive Sleep Apnea (OSA), a large and...

αSK Primers

Inspire Medical Systems’ $150 Million Reimbursement Hit: Can Inspire V Still Deliver?

Inspire Medical Systems reported first quarter fiscal 2026 results characterized by modest revenue growth alongside ongoing challenges related to...

Baptista Research

Inspire Medical Systems: What The New Center Opening Strategy Reveals About The Next Growth Phase!

Inspire Medical Systems, a company focused on innovating treatments for Obstructive Sleep Apnea (OSA), showcased mixed results and future...

Baptista Research

Weekly Stock Bullfinder - Week of 5/15

One of the lasting legacies of the COVID-19 pandemic was the acceleration of secular trends which were already in place prior to the start pandemic...

Weekly Stock Bull Finder

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)